论文部分内容阅读
目的:比较2种新辅助化疗方案治疗乳腺癌的经济学效果。方法:80例乳腺癌患者随机均分为CTF组(环磷酰胺+吡柔比星+5-氟尿嘧啶)和TT组(吡柔比星+紫衫醇)组,新辅助化疗3～4周为1个周期,所有患者在完成2个周期新辅助化疗后进行成本-效果分析。结果:CTF组与TT组的成本分别为2850.00元、5145.00元,总有效率分别为52.5%、82.5%(P<0.05),成本-效果比分别为5428.57、6236.36。结论:CTF组的治疗方案为优选方案。
Objective: To compare the economic effects of two neoadjuvant chemotherapy regimens in the treatment of breast cancer. Methods: Eighty patients with breast cancer were randomly divided into CTF group (cyclophosphamide + pirarubicin + 5-fluorouracil) and TT group (pirarubicin + paclitaxel). Neoadjuvant chemotherapy for 3 to 4 weeks One cycle, all patients performed cost-effectiveness analysis after completing two cycles of neoadjuvant chemotherapy. Results: The costs of CTF group and TT group were 2850.00 yuan and 5145.00 yuan, respectively. The total effective rates were 52.5% and 82.5% respectively (P <0.05), and the cost-effectiveness ratios were 5428.57 and 6236.36 respectively. Conclusion: The treatment of CTF group is the best option.